Lihui Wei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lihui Wei has a total of 422 co-authors. Here are the top co-authors by number of shared publications:
- Jianliu Wang
Peking University People’s Hospital
63 shared publications - Xiao-Ping Li
Department of Gynecology, Peking University People's Hospital, Beijing 100044, China
22 shared publications Chao Zhao
Department of Obstetrics and Gynaecology, Peking University People’s Hospital
20 shared publicationsMingzhu Li
Department of Obstetrics and Gynaecology, Peking University People’s Hospital
20 shared publicationsYun Zhao
Department of Obstetrics and Gynaecology, Peking University People’s Hospital
18 shared publicationsJingran Li
Department of Obstetrics and Gynaecology, Peking University People’s Hospital
17 shared publications
Latest Publications
- Open Access
Is Endocervical Curettage (ECC) Necessary for All HPV16/18-Positive Patients? A Stratified Analysis of 670 Cases
Background: High-risk HPV16/18 subtypes account for over 70% of cervical cancers, but should all HPV16/18-positive patients routinely undergo endocervical curettage (ECC)? Methods: A retrospective cohort study was conducted on 670 HPV16/18-positive patients who underwent colposcopy at Peking University People’s Hospital from 2021 to 2024. Stratified analysis was performed based on prior HPV infection history, current cervical cytology and HPV test results, transformation zone (TZ) type, and colposcopic impression. Primary outcome was the detection rate of cervical intraepithelial neoplasia above (CIN2)+ on final pathology and the additional diagnostic yield of ECC in the ECC subgroup. Results: Among the 670 HPV16/18-positive women, CIN2+ was identified in 32.5% (218/670); the CIN2+ group was significantly younger than the < CIN2 group (median 36.5 vs. 41.0 years, p < 0.001). A high-grade colposcopic impression (G2) steeply elevated the observed CIN2+ proportion to 100%, especially combined with high-grade cytology. In contrast, a Normal/G1 colposcopic finding effectively downgraded the risk to 4.8% in the presence of prior HPV negativity + low-grade cytology + visible TZ. Among the 523 ECC specimens, it is noteworthy that even when the final pathology was diagnosed as CIN2+, a considerably high proportion of patients (44.4–64.7%) remained free of lesions in the endocervical canal; in the colposcopy impression (G2) population, 68.1% of the ECC was normal. The incremental yield of ECC over directed biopsy was only 2.7% (14/523), and all 14 incremental cases occurred in TZ3 (100%). Among the 146 women meeting the composite low-risk profile (TZ1/2 combined with a Normal/G1 colposcopic impression), none had an incremental CIN2+ detection. Conclusion: Women with HPV16/18-positive CIN2+ lesions presented at a younger age. Approximately one-third were diagnosed with CIN2+, and more than half of these had normal ECC histology. With a low additional diagnostic rate observed, ECC provided incremental diagnostic benefit in only 2.7% of HPV16/18-positive women undergoing colposcopy, almost exclusively among patients with a Type 3 transformation zone. The composite low-risk profile identified a subgroup with an extremely low additional diagnostic yield of ECC; however, prospective validation is required before the omission of ECC in this subgroup can be recommended as a change in clinical practice.
Open AccessIs Endocervical Curettage (ECC) Necessary for All HPV16/18-Positive Patients? A Stratified Analysis of 670 Cases
Background: High-risk HPV16/18 subtypes account for over 70% of cervical cancers, but should all HPV16/18-positive patients routinely undergo endocervical curettage (ECC)? Methods: A retrospective cohort study was conducted on 670 HPV16/18-positive patients who underwent colposcopy at Peking University People’s Hospital from 2021 to 2024. Stratified analysis was performed based on prior HPV infection history, current cervical cytology and HPV test results, transformation zone (TZ) type, and colposcopic impression. Primary outcome was the detection rate of cervical intraepithelial neoplasia above (CIN2)+ on final pathology and the additional diagnostic yield of ECC in the ECC subgroup. Results: Among the 670 HPV16/18-positive women, CIN2+ was identified in 32.5% (218/670); the CIN2+ group was significantly younger than the < CIN2 group (median 36.5 vs. 41.0 years, p < 0.001). A high-grade colposcopic impression (G2) steeply elevated the observed CIN2+ proportion to 100%, especially combined with high-grade cytology. In contrast, a Normal/G1 colposcopic finding effectively downgraded the risk to 4.8% in the presence of prior HPV negativity + low-grade cytology + visible TZ. Among the 523 ECC specimens, it is noteworthy that even when the final pathology was diagnosed as CIN2+, a considerably high proportion of patients (44.4–64.7%) remained free of lesions in the endocervical canal; in the colposcopy impression (G2) population, 68.1% of the ECC was normal. The incremental yield of ECC over directed biopsy was only 2.7% (14/523), and all 14 incremental cases occurred in TZ3 (100%). Among the 146 women meeting the composite low-risk profile (TZ1/2 combined with a Normal/G1 colposcopic impression), none had an incremental CIN2+ detection. Conclusion: Women with HPV16/18-positive CIN2+ lesions presented at a younger age. Approximately one-third were diagnosed with CIN2+, and more than half of these had normal ECC histology. With a low additional diagnostic rate observed, ECC provided incremental diagnostic benefit in only 2.7% of HPV16/18-positive women undergoing colposcopy, almost exclusively among patients with a Type 3 transformation zone. The composite low-risk profile identified a subgroup with an extremely low additional diagnostic yield of ECC; however, prospective validation is required before the omission of ECC in this subgroup can be recommended as a change in clinical practice.
- Open Access
- 28 September 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1920297
A multi-centre study on cervical cancer screening reveals population-related impact on cervical intraepithelial neoplasia rate
Objective: To conduct a three-year cervical cancer screen in Zhejiang, Sichuan, Beijing, and Inner Mongolia and analyse clinical and population data to identify possible improvements to the screening protocol. Methods: A standard protocol including human papillomavirus (HPV) detection, cytology test, colposcopy, and histopathology inspection was adapted for the screening. Additional HPV genotyping was performed for participants in Sichuan, Beijing, and Inner Mongolia. Results: 12,086 women were included in this study, and 178 cases of cervical intraepithelial neoplasia (CIN) grade 2 or worse (CIN2+) were identified. Detailed analyses on features of age, region, ethnicity, and origin showed a notable correlation between age strata and high-grade CIN rates. Moreover, apart from HPV16/18, other HPV types such as HPV33, HPV52, and HPV58 were found to be enriched in high-grade CIN cases, as was repeat positivity. Conclusions: Our results suggest that age, HPV16, and ThinPrep cytologic test (TCT) are prominent exploratory predictors for CIN2+ detection, and HPV33, 52, and 58 may pose higher risks than other non-HPV16/18 types. Future studies incorporating prospective effectiveness and health-economic evaluation are required to validate the clinical utility of these predictors.
- 28 September 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1920297
Open AccessA multi-centre study on cervical cancer screening reveals population-related impact on cervical intraepithelial neoplasia rate
Objective: To conduct a three-year cervical cancer screen in Zhejiang, Sichuan, Beijing, and Inner Mongolia and analyse clinical and population data to identify possible improvements to the screening protocol. Methods: A standard protocol including human papillomavirus (HPV) detection, cytology test, colposcopy, and histopathology inspection was adapted for the screening. Additional HPV genotyping was performed for participants in Sichuan, Beijing, and Inner Mongolia. Results: 12,086 women were included in this study, and 178 cases of cervical intraepithelial neoplasia (CIN) grade 2 or worse (CIN2+) were identified. Detailed analyses on features of age, region, ethnicity, and origin showed a notable correlation between age strata and high-grade CIN rates. Moreover, apart from HPV16/18, other HPV types such as HPV33, HPV52, and HPV58 were found to be enriched in high-grade CIN cases, as was repeat positivity. Conclusions: Our results suggest that age, HPV16, and ThinPrep cytologic test (TCT) are prominent exploratory predictors for CIN2+ detection, and HPV33, 52, and 58 may pose higher risks than other non-HPV16/18 types. Future studies incorporating prospective effectiveness and health-economic evaluation are required to validate the clinical utility of these predictors.
- Open Access
- 10 July 2026
- Published by Springer Nature in Clinical Epigenetics
- Vol. 18 (1)
Preliminary study on PAX1/JAM3 methylation and HPV viral load in CIN3-like squamous cell carcinoma: Are there differences from CIN3 and early invasive carcinoma?
Cervical intraepithelial neoplasia grade 3 (CIN 3)-like squamous cell carcinoma (SCC) is a recently identified subtype of cervical cancer with a deceptive
- 10 July 2026
- Published by Springer Nature in Clinical Epigenetics
- Vol. 18 (1)
Open AccessPreliminary study on PAX1/JAM3 methylation and HPV viral load in CIN3-like squamous cell carcinoma: Are there differences from CIN3 and early invasive carcinoma?
Cervical intraepithelial neoplasia grade 3 (CIN 3)-like squamous cell carcinoma (SCC) is a recently identified subtype of cervical cancer with a deceptive
- Open Access
- 12 January 2026
- Published by Springer Nature in Systematic Reviews
- Vol. 15 (1)
Comparison of different mRNA testing technologies with HPV DNA testing for predicting ASCUS triage and post-cone excision outcomes: a systematic review and meta-analysis
Human Papillomavirus (HPV) E6/E7 mRNA testing has been proposed as a potential improvement over HPV DNA testing for predicting cervical lesion progression.
- 12 January 2026
- Published by Springer Nature in Systematic Reviews
- Vol. 15 (1)
Open AccessComparison of different mRNA testing technologies with HPV DNA testing for predicting ASCUS triage and post-cone excision outcomes: a systematic review and meta-analysis
Human Papillomavirus (HPV) E6/E7 mRNA testing has been proposed as a potential improvement over HPV DNA testing for predicting cervical lesion progression.
- Open Access
- 18 September 2025
- Published by BMJ in Gynecology and Obstetrics Clinical Medicine
- Vol. 5 (3) , e000285
Guidelines for the clinical application of prophylactic human papillomavirus (HPV) vaccines in China (2025 edition)
Prophylactic human papillomavirus (HPV) vaccination is a primary preventive measure aimed at preventing HPV-related lesions and cancers by preventing HPV infection. With the continuous update of global data on HPV vaccination, seven academic societies—including the Chinese Society for Colposcopy and Cervical Pathology of China Healthy Birth Science Association and Chinese Society of Gynecological oncology, Chinese Medical Association and others—have jointly developed the Guidelines for the Clinical Application of Prophylactic Human Papillomavirus (HPV) Vaccines in China (2025 Edition). This guideline was based on the previous Chinese Expert Consensus on the Clinical Application of Human Papillomavirus Vaccines1 as well as current evidence-based medical research, China’s national conditions and clinical realities. The recommended categories of this guideline are listed in table 1.
- 18 September 2025
- Published by BMJ in Gynecology and Obstetrics Clinical Medicine
- Vol. 5 (3) , e000285
Open AccessGuidelines for the clinical application of prophylactic human papillomavirus (HPV) vaccines in China (2025 edition)
Prophylactic human papillomavirus (HPV) vaccination is a primary preventive measure aimed at preventing HPV-related lesions and cancers by preventing HPV infection. With the continuous update of global data on HPV vaccination, seven academic societies—including the Chinese Society for Colposcopy and Cervical Pathology of China Healthy Birth Science Association and Chinese Society of Gynecological oncology, Chinese Medical Association and others—have jointly developed the Guidelines for the Clinical Application of Prophylactic Human Papillomavirus (HPV) Vaccines in China (2025 Edition). This guideline was based on the previous Chinese Expert Consensus on the Clinical Application of Human Papillomavirus Vaccines1 as well as current evidence-based medical research, China’s national conditions and clinical realities. The recommended categories of this guideline are listed in table 1.
- Open Access
- 17 September 2025
- Published by BMJ in Gynecology and Obstetrics Clinical Medicine
- Vol. 5 (3) , e000272
Expert consensus on quality control of colposcopy
Cervical cancer is one of the main malignant tumours threatening women’s health. In 2022, there were 661 000 new cases and 348 000 deaths from cervical cancer worldwide.1 In China, there were about 150 700 new cases and 55 700 deaths from cervical cancer in 2022.2
- 17 September 2025
- Published by BMJ in Gynecology and Obstetrics Clinical Medicine
- Vol. 5 (3) , e000272
Open AccessExpert consensus on quality control of colposcopy
Cervical cancer is one of the main malignant tumours threatening women’s health. In 2022, there were 661 000 new cases and 348 000 deaths from cervical cancer worldwide.1 In China, there were about 150 700 new cases and 55 700 deaths from cervical cancer in 2022.2
- Open Access
- 1 July 2025
- Published by BMJ in BMJ Public Health
- Vol. 3 (2) , e001565
Distribution and extended triage of high-risk human papillomavirus genotyping based on vaginal self-sampling
Background: To investigate the overall and type-specific prevalence of high-risk human papillomavirus (HR-HPV) infection in China across different age groups and regions and to evaluate the triage of HPV-positive cases. Methods: A prospective cross-sectional study recruited a total of 20 103 women aged 30–59 years from 13 provinces in China. Self-collected vaginal samples were tested for 14 HR-HPV types using next-generation sequencing or multiplex real-time PCR assays. Results: The five most common types were HPV52, 58, 16, 39 and 51. The prevalence of single-type HR-HPV was 10.70%. The overall proportion of HPV16/18 was 20.67%, with a significant difference observed among provinces (p<0.05). The age-specific prevalence curve of HR-HPV followed a U-shaped pattern from 30 to 59 years, with a lower prevalence observed in women aged 40–44 years (12.35%), which subsequently changed with age. The proportion of women aged 30–34 years with HPV16 (21.59%) was significantly higher than that in other age groups, showing two peaks in young and older women. There was a significantly higher prevalence of HPV16 single-type infection in the youngest group, whereas HPV16 multi-type infection was higher in older women. Among cervical intraepithelial neoplasia grade 2 or higher (CIN)2+ cases, HPV16 infection accounted for 43.98%, HPV18 infection for 7.84%, and other 12 infections for 48.20%. HPV16 had the highest sensitivity for detecting CIN2+, reaching 42.7% among single HPV types, followed by HPV52 and HPV58. When HPV16/18/33 were combined for detection, the sensitivity for detecting CIN2+ increased to 66.67%. Conclusions: The prevalence and genotype distribution of HR-HPV based on vaginal self-sampling varied across different regions and ages in China. HPV16 was more prevalent in both younger and older age groups. Different HPV subtypes have different detection rates for CIN2+, and combining HPV16/18/33 significantly improved the sensitivity for detecting CIN2+.
- 1 July 2025
- Published by BMJ in BMJ Public Health
- Vol. 3 (2) , e001565
Open AccessDistribution and extended triage of high-risk human papillomavirus genotyping based on vaginal self-sampling
Background: To investigate the overall and type-specific prevalence of high-risk human papillomavirus (HR-HPV) infection in China across different age groups and regions and to evaluate the triage of HPV-positive cases. Methods: A prospective cross-sectional study recruited a total of 20 103 women aged 30–59 years from 13 provinces in China. Self-collected vaginal samples were tested for 14 HR-HPV types using next-generation sequencing or multiplex real-time PCR assays. Results: The five most common types were HPV52, 58, 16, 39 and 51. The prevalence of single-type HR-HPV was 10.70%. The overall proportion of HPV16/18 was 20.67%, with a significant difference observed among provinces (p<0.05). The age-specific prevalence curve of HR-HPV followed a U-shaped pattern from 30 to 59 years, with a lower prevalence observed in women aged 40–44 years (12.35%), which subsequently changed with age. The proportion of women aged 30–34 years with HPV16 (21.59%) was significantly higher than that in other age groups, showing two peaks in young and older women. There was a significantly higher prevalence of HPV16 single-type infection in the youngest group, whereas HPV16 multi-type infection was higher in older women. Among cervical intraepithelial neoplasia grade 2 or higher (CIN)2+ cases, HPV16 infection accounted for 43.98%, HPV18 infection for 7.84%, and other 12 infections for 48.20%. HPV16 had the highest sensitivity for detecting CIN2+, reaching 42.7% among single HPV types, followed by HPV52 and HPV58. When HPV16/18/33 were combined for detection, the sensitivity for detecting CIN2+ increased to 66.67%. Conclusions: The prevalence and genotype distribution of HR-HPV based on vaginal self-sampling varied across different regions and ages in China. HPV16 was more prevalent in both younger and older age groups. Different HPV subtypes have different detection rates for CIN2+, and combining HPV16/18/33 significantly improved the sensitivity for detecting CIN2+.
- Open Access
- 27 May 2025
- Published by BMJ in Gynecology and Obstetrics Clinical Medicine
- Vol. 5 (2) , e000205
Guidelines for cervical cancer screening in China II
Cervical cancer is a common malignant tumour that has become a major global public health issue, seriously threatening women’s lives. In November 2020, the WHO released a global strategy to accelerate the elimination of cervical cancer as a public health problem. So far, the proposal has received positive responses and commitments from 194 countries around the world, including China, which has actively promoted the prevention and treatment of cervical cancer nationwide. In support of the WHO initiative, in January 2023, the Chinese National Health Commission, along with other entities, issued a 7-year Action Plan for Accelerating the Elimination of Cervical Cancer (2023–2030), which primarily focused on improving the cervical cancer prevention and control service system and on strengthening its overall capacity. Furthermore, based on research evidence and practical experience, experts from seven Chinese academic societies—including the Chinese Society for Colposcopy and Cervical Pathology of China Healthy Birth Science Association and Chinese Society of Gynecological Oncology, Chinese Medical Association—have recently published the Guidelines for cervical cancer screening in China II (Guideline II). Unlike the previous Guidelines for cervical cancer screening in China I (Guideline I),1 which primarily focused on primary screening methods for cervical cancer, Guideline II emphasises the management and triage of abnormal primary screening results. As part of tertiary prevention, both screening and triage are critical steps in preventing the progression of cervical cancer, especially for those with abnormal test results. Here, we present a new guideline focused on standardising the triage of abnormal cervical cancer screening to improve management, reduce missed diagnoses and prevent overdiagnosis.
- 27 May 2025
- Published by BMJ in Gynecology and Obstetrics Clinical Medicine
- Vol. 5 (2) , e000205
Open AccessGuidelines for cervical cancer screening in China II
Cervical cancer is a common malignant tumour that has become a major global public health issue, seriously threatening women’s lives. In November 2020, the WHO released a global strategy to accelerate the elimination of cervical cancer as a public health problem. So far, the proposal has received positive responses and commitments from 194 countries around the world, including China, which has actively promoted the prevention and treatment of cervical cancer nationwide. In support of the WHO initiative, in January 2023, the Chinese National Health Commission, along with other entities, issued a 7-year Action Plan for Accelerating the Elimination of Cervical Cancer (2023–2030), which primarily focused on improving the cervical cancer prevention and control service system and on strengthening its overall capacity. Furthermore, based on research evidence and practical experience, experts from seven Chinese academic societies—including the Chinese Society for Colposcopy and Cervical Pathology of China Healthy Birth Science Association and Chinese Society of Gynecological Oncology, Chinese Medical Association—have recently published the Guidelines for cervical cancer screening in China II (Guideline II). Unlike the previous Guidelines for cervical cancer screening in China I (Guideline I),1 which primarily focused on primary screening methods for cervical cancer, Guideline II emphasises the management and triage of abnormal primary screening results. As part of tertiary prevention, both screening and triage are critical steps in preventing the progression of cervical cancer, especially for those with abnormal test results. Here, we present a new guideline focused on standardising the triage of abnormal cervical cancer screening to improve management, reduce missed diagnoses and prevent overdiagnosis.
- Open Access
- 13 March 2025
- Published by BMJ in Gynecology and Obstetrics Clinical Medicine
- Vol. 5 (1) , e000151
Science education guide to cervical cancer prevention and treatment in China
Cervical cancer remains a significant threat to the health and lives of Chinese women. In 2022 alone, national cancer registry data reported 150 700 new cervical cancer cases and 55 700 deaths, with a global age-standardised incidence rate of 13.83/100 000 and a mortality rate of 4.54/100 000, representing 6.58% and 5.89% of all female cancer cases and deaths, respectively. 1 Since 2000, both incidence and mortality rates in China have continued to rise, with cases increasingly occurring in younger women. Although three-tier prevention and treatment measures for cervical cancer exist, China’s current prevention and treatment service infrastructure remains incomplete. Gaps in women’s health awareness, limited access to relevant information, low rates of human papillomavirus (HPV) vaccination and insufficient cervical cancer screening coverage continue to pose challenges.2 3
- 13 March 2025
- Published by BMJ in Gynecology and Obstetrics Clinical Medicine
- Vol. 5 (1) , e000151
Open AccessScience education guide to cervical cancer prevention and treatment in China
Cervical cancer remains a significant threat to the health and lives of Chinese women. In 2022 alone, national cancer registry data reported 150 700 new cervical cancer cases and 55 700 deaths, with a global age-standardised incidence rate of 13.83/100 000 and a mortality rate of 4.54/100 000, representing 6.58% and 5.89% of all female cancer cases and deaths, respectively. 1 Since 2000, both incidence and mortality rates in China have continued to rise, with cases increasingly occurring in younger women. Although three-tier prevention and treatment measures for cervical cancer exist, China’s current prevention and treatment service infrastructure remains incomplete. Gaps in women’s health awareness, limited access to relevant information, low rates of human papillomavirus (HPV) vaccination and insufficient cervical cancer screening coverage continue to pose challenges.2 3
- Open Access
- 23 November 2024
- Published by Elsevier in Photodiagnosis and Photodynamic Therapy
- Vol. 50, 104422
Hiporfin photodynamic therapy for early-stage cervical cancer: A case report
- 23 November 2024
- Published by Elsevier in Photodiagnosis and Photodynamic Therapy
- Vol. 50, 104422
Open AccessHiporfin photodynamic therapy for early-stage cervical cancer: A case report